2023 Alzheimer’s disease facts and figures. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2023;19(4):1598 – 695.
Jellinger KA. Neuropathological assessment of the Alzheimer spectrum. J Neural Transm (Vienna). 2020;127(9):1229–56.
Tao Q, Ang TFA, DeCarli C, Auerbach SH, Devine S, Stein TD, et al. Association of Chronic Low-grade inflammation with risk of Alzheimer Disease in ApoE4 carriers. JAMA Netw Open. 2018;1(6):e183597.
Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res. 2012;43(8):600–8.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–27.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21.
Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and beta-amyloid-targeting antibodies: a systematic review. JAMA Neurol. 2022;79(3):291–304.
Alves F, Kalinowski P, Ayton S. Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and Meta-analysis. Neurology. 2023;100(20):e2114–24.
Athar T, Al Balushi K, Khan SA. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Mol Biol Rep. 2021;48(7):5629–45.
Yu TW, Lane HY, Lin CH. Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review. Int J Mol Sci. 2021;22(15).
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2023. Alzheimer’s Dementia: Translational Res Clin Interventions. 2023;9(2):e12385.
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Investig. 2012;122(4):1316–38.
Gu Xea. Serine 616 phosphorylation of insulin receptor substrate-1 (IRS-1 pS616) pathology in hippocampal field CA1 as a biomarker of Alzheimer’ disease (AD) verified in 82 cases from 3 brain banks using artificial intelligence (AI)-based image analysis. Abstract PSTR 198. 2023;Soceity for Neuroscience Meeting(Washington, D.C.).
Rhea EM, Leclerc M, Yassine HN, Capuano AW, Tong H, Petyuk VA et al. State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer’s Disease. Aging Dis. 2023.
Sedzikowska A, Szablewski L. Insulin and Insulin Resistance in Alzheimer’s Disease. Int J Mol Sci. 2021;22(18).
Colin IM, Szczepanski LW, Gerard AC, Elosegi JA. Emerging evidence for the use of Antidiabetic Drugs, glucagon-like peptide 1 receptor agonists, for the treatment of Alzheimer’s Disease. touchREV Endocrinol. 2023;19(1):16–24.
Folch J, Olloquequi J, Ettcheto M, Busquets O, Sanchez-Lopez E, Cano A, et al. The involvement of peripheral and brain insulin resistance in late Onset Alzheimer’s dementia. Front Aging Neurosci. 2019;11:236.
Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22(6):423–36.
Kellar D, Craft S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758–66.
Yamamoto N, Matsubara T, Sobue K, Tanida M, Kasahara R, Naruse K, et al. Brain insulin resistance accelerates Abeta fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J Neurochem. 2012;121(4):619–28.
Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem. 2009;284(28):18742–53.
Vandal M, Bourassa P, Calon F. Can insulin signaling pathways be targeted to transport Abeta out of the brain? Front Aging Neurosci. 2015;7:114.
Tokutake T, Kasuga K, Yajima R, Sekine Y, Tezuka T, Nishizawa M, et al. Hyperphosphorylation of Tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3beta signaling pathway. J Biol Chem. 2012;287(42):35222–33.
Nistico R, Cavallucci V, Piccinin S, Macri S, Pignatelli M, Mehdawy B, et al. Insulin receptor beta-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory. Neuromolecular Med. 2012;14(4):262–9.
Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol Neurobiol. 2013;47(1):145–71.
Grillo CA, Piroli GG, Lawrence RC, Wrighten SA, Green AJ, Wilson SP, et al. Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. Diabetes. 2015;64(11):3927–36.
Biessels GJ, Reagan LP. Hippocampal insulin resistance and cognitive dysfunction. Nat Rev Neurosci. 2015;16(11):660–71.
Milstein JL, Ferris HA. The brain as an insulin-sensitive metabolic organ. Mol Metab. 2021;52:101234.
Liu Q, Wang Z, Cao J, Dong Y, Chen Y. The Role of Insulin Signaling in Hippocampal-Related Diseases: A Focus on Alzheimer’s Disease. Int J Mol Sci. 2022;23(22).
Derakhshan F, Toth C. Insulin and the brain. Curr Diabetes Rev. 2013;9(2):102–16.
Rhea EM, Banks WA, Raber J. Insulin Resistance in Peripheral tissues and the brain: a tale of two sites. Biomedicines. 2022;10(7).
Meng L, Li XY, Shen L, Ji HF. Type 2 diabetes Mellitus drugs for Alzheimer’s Disease: current evidence and Therapeutic opportunities. Trends Mol Med. 2020;26(6):597–614.
Yang JJ. Brain insulin resistance and the therapeutic value of insulin and insulin-sensitizing drugs in Alzheimer’s disease neuropathology. Acta Neurol Belg. 2022;122(5):1135–42.
Goodarzi G, Tehrani SS, Fana SE, Moradi-Sardareh H, Panahi G, Maniati M, et al. Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs. Metab Brain Dis. 2023;38(6):1769–800.
Mantik KEK, Kim S, Gu B, Moon S, Kwak HB, Park DH et al. Repositioning of anti-diabetic drugs against Dementia: insight from molecular perspectives to clinical trials. Int J Mol Sci. 2023;24(14).
Pradhan SP, Sahu PK, Behera A. New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer’s disease. Mol Cell Biochem. 2023;478(12):2739–62.
Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology. 2011;60(6):910–20.
Ruegsegger GN, Vanderboom PM, Dasari S, Klaus KA, Kabiraj P, McCarthy CB et al. Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain. JCI Insight. 2019;4(18).
Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology. 2012;153(1):329–38.
Hu SH, Jiang T, Yang SS, Yang Y. Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2013;121(4):220–4.
Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43–50.
Kullmann S, Hummel J, Wagner R, Dannecker C, Vosseler A, Fritsche L, et al. Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a Randomized, Double-Blind, Placebo-Controlled, phase 2 trial. Diabetes Care. 2022;45(2):398–406.
Talbot KaW H-Y. Developing CNS therapeutics for brain insulin resistance in Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Alzheimer’s Dement. 2020;16(3):e039514.
Nowell J, Blunt E, Edison P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease. Mol Psychiatry. 2023;28(1):217–29.
Wu CY, Ouk M, Wong YY, Anita NZ, Edwards JD, Yang P, et al. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer’s disease, and the role APOE carrier status. Alzheimer’s Dement J Alzheimer’s Assoc. 2020;16(12):1663–73.
Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, et al. Metformin in amnestic mild cognitive impairment: results of a pilot randomized Placebo Controlled Clinical Trial. J Alzheimers Dis. 2016;51(2):501–14.
Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the insulin sensitizer Metformin in Alzheimer Disease: Pilot Data from a Randomized Placebo-controlled crossover study. Alzheimer Dis Assoc Disord. 2017;31(2):107–13.
Nelson ML, Pfeifer JA, Hickey JP, Collins AE, Kalisch BE. Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor. Biology (Basel). 2023;12(7).
Saunders AM, Burns DK, Gottschalk WK. Reassessment of Pioglitazone for Alzheimer’s Disease. Front Neurosci. 2021;15:666958.
Lin HC, Chung CH, Chen LC, Wang JY, Chen CC, Huang KY, et al. Pioglitazone use increases risk of Alzheimer’s disease in patients with type 2 diabetes receiving insulin. Sci Rep. 2023;13(1):6625.
Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S, et al. Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J Am Geriatr Soc. 2023;71(7):2096–106.
De Giorgi R, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClinicalMedicine. 2024:102726.
Norgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Moller DV, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer’s Dementia: Translational Res Clin Interventions. 2022;8(1):e12268.
Siao WZ, Lin TK, Huang JY, Tsai CF, Jong GP. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study. Diab Vasc Dis Res. 2022;19(3):14791641221098168.
Wium-Andersen IK, Osler M, Jorgensen MB, Rungby J, Wium-Andersen MK. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur J Endocrinol. 2019;181(5):499–507.
Zhou B, Zissimopoulos J, Nadeem H, Crane MA, Goldman D, Romley JA. Association between exenatide use and incidence of Alzheimer’s disease. Alzheimer’s Dementia: Translational Res Clin Interventions. 2021;7(1):e12139.
Akimoto H, Negishi A, Oshima S, Wakiyama H, Okita M, Horii N, et al. Antidiabetic drugs for the risk of Alzheimer Disease in patients with type 2 DM using FAERS. Am J Alzheimers Dis Other Demen. 2020;35:1533317519899546.
Zhang ZQ, Holscher C. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models. Peptides. 2020;125:170184.
Liu XY, Zhang N, Zhang SX, Xu P. Potential new therapeutic target for Alzheimer’s disease: glucagon-like peptide-1. Eur J Neurosci. 2021;54(10):7749–69.
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–37.
Cheang JY, Moyle PM. Glucagon-like Peptide-1 (GLP-1)-Based therapeutics: current Status and Future opportunities beyond type 2 diabetes. ChemMedChem. 2018;13(7):662–71.
Reich N, Holscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: an in-depth review. Front Neurosci. 2022;16:970925.
Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4(10):718–31.
Paratore S, Ciotti MT, Basille M, Vaudry D, Gentile A, Parenti R, et al. Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival. Cent Nerv Syst Agents Med Chem. 2011;11(3):210–22.
Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics. Biochem Pharmacol. 2020;180:114187.
Rhea EM, Babin A, Thomas P, Omer M, Weaver R, Hansen K et al. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases. Tissue Barriers. 2023:2292461.
Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 receptor agonists Associated Gastrointestinal adverse events: a Cross-sectional Analysis of the National Institutes of Health all of us Cohort. Pharmaceuticals (Basel). 2024;17(2).
Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1).
Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789.
Rhea EM, Salameh TS, Banks WA. Routes for the delivery of insulin to the central nervous system: a comparative review. Exp Neurol. 2019;313:10–5.
Hallschmid M. Intranasal insulin for Alzheimer’s Disease. CNS Drugs. 2021;35(1):21–37.
Rhea EM, Humann SR, Nirkhe S, Farr SA, Morley JE, Banks WA. Intranasal Insulin Transport is preserved in aged SAMP8 mice and is altered by albumin and insulin receptor inhibition. J Alzheimers Dis. 2017;57(1):241–52.
Lochhead JJ, Kellohen KL, Ronaldson PT, Davis TP. Distribution of insulin in trigeminal nerve and brain after intranasal administration. Sci Rep. 2019;9(1):2621.
Jiao SS, Bu XL, Liu YH, Zhu C, Wang QH, Shen LL, et al. Sex Dimorphism Profile of Alzheimer’s Disease-Type pathologies in an APP/PS1 mouse model. Neurotox Res. 2016;29(2):256–66.
Li X, Feng Y, Wu W, Zhao J, Fu C, Li Y, et al. Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer’s disease. Lab Anim. 2016;50(4):275–85.
Eikelboom WS, Pan M, Ossenkoppele R, Coesmans M, Gatchel JR, Ismail Z, et al. Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis. Alzheimers Res Ther. 2022;14(1):48.
Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer’s disease. J Alzheimers Dis. 2013;35(4):789–97.
Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Investig. 2012;122(4):1339–53.
Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc. 2014;10(1 Suppl):S12–25.
Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol. 2004;55(6):801–14.
Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7(9):940–6.
Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24(3):516–24.
Szu JI, Obenaus A. Cerebrovascular phenotypes in mouse models of Alzheimer’s disease. J Cereb Blood flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism. 2021;41(8):1821–41.
Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2001;8(4):555–67.
Do TM, Alata W, Dodacki A, Traversy MT, Chacun H, Pradier L, et al. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer’s disease. Neuropharmacology. 2014;81:311–7.
Rhea EM, Hansen K, Pemberton S, Torres ERS, Holden S, Raber J, et al. Effects of apolipoprotein E isoform, sex, and diet on insulin BBB pharmacokinetics in mice. Sci Rep. 2021;11(1):18636.
Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966;13(8):655–69.
Braak H, Rub U, Schultz C, Del Tredici K. Vulnerability of cortical neurons to Alzheimer’s and Parkinson’s diseases. J Alzheimers Dis. 2006;9(3 Suppl):35–44.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
Monney M, Jornayvaz FR, Gariani K. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab. 2023;49(5):101470.
Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease. Ageing Res Rev. 2023;89:101979.
Holscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs. 2020;29(4):333–48.
Holscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Front Synaptic Neurosci. 2022;14:955258.
Velazquez R, Tran A, Ishimwe E, Denner L, Dave N, Oddo S, et al. Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer’s disease. Neurobiol Aging. 2017;58:1–13.
Lopez-Ferreras L, Eerola K, Mishra D, Shevchouk OT, Richard JE, Nilsson FH, et al. GLP-1 modulates the supramammillary nucleus-lateral hypothalamic neurocircuit to control ingestive and motivated behavior in a sex divergent manner. Mol Metab. 2019;20:178–93.
Schneider AL, Martins-Silva R, Kaizeler A, Saraiva-Agostinho N, Barbosa-Morais NL. voyAGEr: free web interface for the analysis of age-related gene expression alterations in human tissues. Cold Spring Harbor Laboratory; 2022.
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929–47.
Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with Mouse. Neuron. 2016;89(1):37–53.
Rhea EM, Rask-Madsen C, Banks WA. Insulin transport across the blood-brain barrier can occur independently of the insulin receptor. J Physiol. 2018;596(19):4753–65.
Rhea EM, Salameh TS, Gray S, Niu J, Banks WA, Tong J. Ghrelin transport across the blood-brain barrier can occur independently of the growth hormone secretagogue receptor. Mol Metab. 2018;18:88–96.
Add Comment